Loading…
Sarepta Therapeutics, Inc. is projected to rise to $17.37 by 2027, a +17% move from its current price of $14.86. SRPT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $14.49 | $14.86 | $15.25 | +0.03% |
| Aug 3 | $14.35 | $14.87 | $15.41 | +0.06% |
| Aug 4 | $14.23 | $14.87 | $15.54 | +0.08% |
| Aug 5 | $14.14 | $14.88 | $15.65 | +0.11% |
| Aug 6 | $14.06 | $14.88 | $15.75 | +0.14% |
| Aug 7 | $13.99 | $14.88 | $15.84 | +0.17% |
| Aug 8 | $13.92 | $14.89 | $15.92 | +0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $13.92 | $14.89 | $15.92 | +0.20% |
| Week 2 | $13.57 | $14.92 | $16.40 | +0.39% |
| Week 3 | $13.31 | $14.95 | $16.79 | +0.59% |
| Week 4 | $13.10 | $14.98 | $17.12 | +0.79% |
| Week 5 | $12.92 | $15.01 | $17.43 | +0.98% |
| Week 6 | $12.76 | $15.04 | $17.72 | +1.18% |
| Week 7 | $12.62 | $15.07 | $17.99 | +1.38% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University.
The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Sarepta Therapeutics, Inc. (SRPT) operates in the healthcare sector as a biopharmaceutical company focused on RNA-targeted therapies for rare diseases. The description highlights a portfolio of Duchenne disease treatments and gene therapy programs, alongside collaborations with major institutions and companies.
The institution of SRPT in 1980 and its Cambridge, Massachusetts headquarters frame its corporate context.
A major floor 25.4% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 38.1% above — a clean break opens room to run.
A major ceiling 60.0% above — clearing it would confirm fresh momentum.
Key SRPT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SRPT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $15.46 | Sell | $15.41 | Sell |
| MA 10 | $15.77 | Sell | $15.88 | Sell |
| MA 20 | $17.26 | Sell | $16.52 | Sell |
| MA 50 | $16.94 | Sell | $17.29 | Sell |
| MA 100 | $18.51 | Sell | $18.21 | Sell |
| MA 200 | $19.42 | Sell | $22.70 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 31.80 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -106.90 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.25 | Sell |
| ROC (12) | -15.62 | Sell |
| Bollinger %B (20,2) | 0.15 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.29 | Sell |
| Awesome (5,34) | -1.71 | Sell |
| Ultimate (7,14,28) | 20.97 | Buy |
| Momentum (10) | -2.36 | Sell |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 15.22 | Sell |
| ADX (14) | 22.72 | Sell |
| ATR (14) | 0.40 | Info |
Technically, the near term shows bearish undertones with RSI14 at 40 and a 30-day range from $13.40 to $19.61. The SMA50 sits at $17.39, while the SMA200 rests at $19.70, suggesting price may hover between key moving averages.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $14.86 | $14.86 | $19.80 | 0% | Neutral | |
| $13.95 | $17.37 | $22.82 | +17% | Neutral | |
| $14.72 | $18.82 | $25.60 | +27% | Bullish | |
| $14.24 | $18.60 | $26.01 | +25% | Bullish | |
| $13.74 | $18.29 | $26.17 | +23% | Bullish | |
| $14.92 | $20.20 | $29.50 | +36% | Bullish | |
| $14.50 | $19.95 | $29.67 | +34% | Bullish | |
| $15.88 | $22.17 | $33.51 | +49% | Bullish | |
| $18.99 | $26.89 | $41.26 | +81% | Bullish | |
| $18.79 | $26.97 | $41.96 | +81% | Bullish | |
| $22.70 | $34.63 | $57.14 | +133% | Bullish | |
| $37.01 | $62.63 | $112.59 | +321% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $14.86 | $14.86 | $17.85 | +0.00% |
| September 2026 | $12.49 | $14.75 | $17.88 | -0.75% |
| October 2026 | $12.83 | $15.24 | $18.67 | +3.36% |
| November 2026 | $13.28 | $15.86 | $19.58 | +4.06% |
| December 2026 | $13.28 | $15.93 | $19.80 | +0.41% |
Click any year to see its month-by-month SRPT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect SRPT to range from $14.86 to $19.80 through 2026. The $14.86 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The SRPT price prediction for 2027 points to an average of $17.37 (low $13.95, high $22.82) — a potential gain of +17% on today's $14.86. A consolidation phase looks the most probable path here.
In 2028, SRPT is projected to trade between $14.72 and $25.60, averaging $18.82 — a potential gain of +27% from today's $14.86. That is up +8% on the projected 2027 average. Momentum favours further upside here.
Sarepta Therapeutics, Inc.'s 2029 outlook centres on $18.60, within a $14.24 to $26.01 range. That is -1% versus the projected 2028 average. That marks a +25% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, SRPT could reach as high as $26.17, with a base case around $18.29 and support toward $13.74 — roughly +23% from $14.86. Momentum favours further upside here.
Expect SRPT to range from $14.92 to $29.50 through 2031. The $20.20 average target implies a +36% move from current prices. That is up +10% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The SRPT price prediction for 2032 points to an average of $19.95 (low $14.50, high $29.67) — a potential gain of +34% on today's $14.86. Momentum favours further upside here.
In 2033, SRPT is projected to trade between $15.88 and $33.51, averaging $22.17 — a potential gain of +49% from today's $14.86. That is up +11% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Sarepta Therapeutics, Inc.'s 2034 outlook centres on $26.89, within a $18.99 to $41.26 range. That is up +21% on the projected 2033 average. That marks a +81% change versus current levels. Momentum favours further upside here.
By 2035, SRPT could reach as high as $41.96, with a base case around $26.97 and support toward $18.79 — roughly +81% from $14.86. Buyers look set to stay in control over this stretch.
Expect SRPT to range from $22.70 to $57.14 through 2040. The $34.63 average target implies a +133% move from current prices. That is up +28% on the projected 2035 average. Momentum favours further upside here.
The SRPT price prediction for 2050 points to an average of $62.63 (low $37.01, high $112.59) — a potential gain of +321% on today's $14.86. Buyers look set to stay in control over this stretch.
Investing $1,000 in SRPT today (≈ 67.294751 SRPT) could be worth
$4,214.36
+$3,214.36 (+321%) by 2050 · US Dollar
Based on the average projected SRPT price of $62.63 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SRPTwould be worth at today's price.
$1,000 invested in SRPT on Jul 31, 2025 (≈ 60.90134 SRPT) would be worth
$904.99
-$95.01 (-9.5%) today · 0.90× · US Dollar
Based on a SRPT entry price of $16.42 vs. today's $14.86.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $15.68 | $947.7 | -5.2% |
| 1 month ago | $18.2 | $816.48 | -18.4% |
| 3 months ago | $21.49 | $691.48 | -30.9% |
| 6 months ago | $20.72 | $717.18 | -28.3% |
| 1 year ago | $16.42 | $904.99 | -9.5% |
| All time (5.0y) ago | $68.59 | $216.65 | -78.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SRPT forecast.
Our base-case forecast reaches $30.00 around 2040.
Implied market cap at $30.00: $3.17B
The multi-year forecast shows upside potential, with the 2030 average at $20.60 and a 27.1% ROI, rising further to a 2040 average of $41.02 with a 153.1% ROI, and a 2050 average of $74.03 with a 356.7% ROI. The sentiment is bullish across these longer horizons, reflecting anticipated price growth despite the current near-term bearish signal. These figures illustrate a path of substantial appreciation relative to today's level, though they remain estimates and are not guarantees.
Tap a question to reveal the answer.
The forecast for 2030 lists an average price of $20.60 with a minimum of $15.12, a maximum of $30.29 and a ROI of 27.1%, with a bullish sentiment.
The longer-horizon outlook shows bullish sentiment in 2027 ($19.53 avg, ROI 20.5%), 2028 ($20.91 avg, ROI 29%), 2029 ($20.62 avg, ROI 27.2%), 2030 ($20.60 avg, ROI 27.1%), 2040 ($41.02 avg, ROI 153.1%), and 2050 ($74.03 avg, ROI 356.7%). These are estimates and not guarantees.
Yes. The forecast indicates a high of $50.05 in 2034 and $50.04 in 2035.
The current price is $16.21 and the market capitalization is $1.71B, with a rank of 2146.
RSI 14 is 40 with a bearish sentiment. The 30-day range is $13.40 to $19.61, with a SMA50 of $17.39 and a SMA200 of $19.70. Key support is at $15.00 and resistance at $20.52.
Sarepta Therapeutics, Inc. Community Discussion
0Share your Sarepta Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.